Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase

Vascular Pharmacology

Volumn 58, Issue 1-2, 2013, Pages 21-30

  Kwok, Jennifer M F ^a   Ma, Christopher Cheng Hwa ^b   Ma, Sze ^c  

^a St Theresa's Hospital   (Hong Kong)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Hong Kong Baptist Hospital   (Hong Kong)

Author keywords

Cardiovascular disease; NADPH oxidases; Pleiotropic; Rac1; Statin

Indexed keywords

ALPHA CATENIN; ATORVASTATIN; BETA CATENIN; COLESTILAN; CONNECTIVE TISSUE GROWTH FACTOR; CONNEXIN 43; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDOREDUCTASE; PRAVASTATIN; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; SUPEROXIDE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ATHEROSCLEROSIS; BLOOD VESSEL; BRAIN ISCHEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID PEROXIDATION; LYMPHOMA CELL; NERVOUS SYSTEM; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SUBUNIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; THROMBOEMBOLISM; UROGENITAL SYSTEM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NADPH OXIDASE; RAC1 GTP-BINDING PROTEIN;

EID: 84871711868     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.10.003     Document Type: Review

References (87)

1. Adam O., Frost G., Custodis F., Sussman M.A., Schafers F.J., Bohm M., Laufs U. Role of Rac1 GTPase activation in atrial fibrillation. J. Am. Coll. Cardiol. 2007, 50(4):359-367.
2. Adam O., Hagel M., Thoebald K., Bohm M., Laufs U. Inhibitor effect of estrogen on Rac1-expression in monocytes. Biochem. Biophys. Res. Commun. 2009, 386(1):45-49.
3. Adam O., Lavall D., Theobald K., Hohl M., Grube M., Ameling S., Sussman M.A., Rosenkranz S., Kroemer H.K., Schafers H.J., Bohm M., Laufs U. Rac1-induced connective tissue growth factor regulates connexion 43 and N-acadherin expression in atrial fibrillation. J. Am. Coll. Cardiol. 2010, 55(5):469-480.
4. Ago T., Kuroda J., Pain J., Fu C., Li H., Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 2010, 106(7):1253-1264.
5. Alvarez E., Rodino-Janeiro B.K., Ucieda-Somoza R., Gonzalez-Juanatey J.R. Pravastatin counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma membrane of human endothelial cells. J. Cardiovasc. Pharmacol. 2010, 55(2):203-212.
6. Antoniades C., Bakogiannis C., Tousoulis D., Reilly S., Zhang M.H., Paschalis A., et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010, 122(11 Suppl.):S66-S73.
7. Antoniades C., Demosthenous M., Reilly S., Margaritis M., Zhang M.H., Antonopulos A., Marinou K., Nahar K., et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J. Am. Coll. Cardiol. 2012, 59(1):60-70.
8. Baba T.T., Nemoto T.K., Miyazaki T., Oida S. Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. J. Muscle Res. Cell Motil. 2008, 29(2-5):127-134.
9. Basuroy S., Bhattacharya S., Leffler C.W., Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 296(3):C422-C432.
10. Basuroy S., Tcheranova D., Bhattacharya S., Leffler C.W., Parfenova H.K. Nox4 NADPH oxidase-derived reactive oxygen species, via endogenous carbon monoxide, promote survival of brain endothelial cells during TNF-alpha-induced apoptosis. Am. J. Physiol. 2011, 300(2):C256-C265.
11. Briones A.M., Rodriguez-Criado N., Hemanz R., Garcia-Redondo A.B., Rodrigues-Diez R.R., Alonso M.J., Egido J., Ruiz-Ortega M., Salaices M. Atorvastatin prevents angiotensin II-induced vascular remodelling and oxidative stress. Hypertension 2009, 54(1):142-149.
12. Chen L.Y., Mehta J.L. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J. Cardiovasc. Pharmacol. 1996, 27(1):154-158.
13. Chen W.T., Krishnan G.M., Sood N., Kluger J., Coleman C.I. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J. Thorac. Cardiovasc. Surg. 2010, 140(2):364-372.
14. Chiang C.E., Naditch-Brule L., Murin J., Goethals M., Inoue H., O'Neill J., Silva-Cardoso J., Zharinov O., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 2012, 5(4):632-639.
15. Chopra V., Wesorick D.H., Sussman J.B., Greene T., Rogers M., Froehlich J.B., Eagle K.A., Sain S. Effect of perioperative statins on death, myocardial infarction, and atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch. Surg. 2012, 147(2):181-189.
16. Clempus R.E., Sorescu D., Dikalova A.E., Pounkova L., Jo P., Sorescu G.P., et al. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 2007, 27(1):42-48.
17. Cui W., Matsuno K., Iwata K., Ibi M., Katsuyama M., Kakehi T., Sasaki M., Ikami K., Zhu K., Yabe-Nishimura C. NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models. J. Pharmacol. Sci. 2009, 111(3):260-268.
18. Dejana E. Endothelial cell to cell junctions and the control of vascular permeability. Vascul. Pharmacol. 2012, 56(5-6):307.
19. Diebold B.A., Fwolder B., Lu J., Dinauer M.C., Bokoch G.M. Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species. J. Biol. Chem. 2004, 279(27):28136-28142.
20. Dikalova A., Clempus R., Lassegue B., Cheng G., McCoy J., Dikalov S., et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112:2668-2676.
21. Dikalova A., Gongora M., Harrison D., Lambeth D., Dikalov S., Griendling K. Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am. J. Physiol. Heart Circ. Physiol. 2010, 299(3):H673-H679.
22. Ellmark S.H., Dusting G.J., Fui M.N., Guzzo-Pernell N., Drummond G.R. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc. Res. 2005, 65(2):495-504.
23. Erdos B., Snipes J.A., Tulbert C.D., Katakam P., Miller A.W., Busija D.W. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(3):H1264-H1270.
24. Ghittoni R., Patrussi L., Pirozzi K., Pellegrini M., Lazzerini P.E., Capecchi P.L., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 2005, 19(6):605-607.
25. Giunti S., Calkin A.C., Forbes J.M., Allen T.J., Thomas M.C., Cooper M.E., Jandeleit-Dahm K.A. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am. J. Physiol. Renal Physiol. 2010, 299(3):F528-F535.
26. Guzik T.J., Chen W., Gongora M.C., Guzik B., Lob H.E., Mangalat D., et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 2008, 52(22):1803-1809.
27. Habibi J., Whaley-Connell A., Qazi M.A., Hayden M.R., Cooper S.A., Tramontano A., et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007, 148(5):2181-2188.
28. Hamilton P.K., Hughes S.M., Plumb R.D., Devine A., Leahey W., Lyons K.S., et al. Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia. Clin. Sci. (Lond.) 2010, 118(5):359-366.
29. Haramaki N., Ikeda H., Takenaka K., Katoh A., Sugano R., Yamagishi S., et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler. Thromb. Vasc. Biol. 2007, 27(6):1471-1477. (Jun).
30. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their function from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9(9):690-701.
31. Hoang V.M., Nagy J.A., Senger D.R. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood 2011, 117(5):1751-1760.
32. Hong H., Zeng J.S., Kreulen D.L., Kaufman D.I., Chen A.F. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(5):H2210-H2215.
33. Ismail S., Sturrock A., Wu P., Cahill B., Norman K., Huecksteadt T., et al. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-[U+FE5B]beta[U+FE5C]1 and insulin-like growth factor binding protein-3. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296(3):L489-L499.
34. Jackman K.A., Miller A.A., Drummond G.R., Sobey C.G. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res. 2009, 1286:215-220.
35. Jaquet V., Scapozza L., Clark R.A., Krause K.H., Lambeth J.D. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid. Redox Signal. 2009, 11(10):2535-2552.
36. Judkins C.P., Diep H., Broughton B.R., Mast A.E., Hooker E.U., Miller A.A., et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/-mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(1):H24-H32.
37. Kahles T., Luedike P., Endres M., Galla H.J., Steinmetz H., Busse R., et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007, 38(11):3000-3006.
38. Kahles T., Kohnen A., Heumueller S., Rappert A., Bechmann I., Liebner S., et al. NADPH oxidase Nox1 contributes to ischemic injury in experimental stoke in mice. Neurobiol. Dis. 2010, 40(1):185-192.
39. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., Pillai R., Channon K.M., Cassadei B. A myocardial NOX2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 2005, 97(7):629-636.
40. Kurisu S., Takenawa T. The WASP and WAVE family proteins. Genome Biol. 2009, 10(6):226.
41. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M.D., Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(35):15565-15570.
42. Lassegue B., Griendling K.K. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 2010, 30(4):653-661.
43. Laufs U., Adam O., Strehlow K., Wassmann S., Konkol C., Laufs K., Schmidt W., Bohm M., Nickenig G. Down-regulation of Rac-1 GTPase by estrogen. J. Biol. Chem. 2003, 278(8):5956-5962.
44. Laufs U., Wassmann S., Czech T., Munzel T., Eisenhauer M., Bohm M., Nickenig G. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25(4):809-814.
45. Liakopoulos O.J., Choi Y.H., Kuhn E.W., Wittwer T., Borys M., Madershahian N., Wassmer G., Wahlers T. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J. Thorac. Cardiovasc. Surg. 2009, 138(3):678-686.
46. Liakopoulos O.J., Kuhn E.W., Slottosch I., Wassmer G., Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst. Rev. 2012, 4:CD008493.
47. Liang S.L., Liu H., Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J. Immunol. 2006, 177(1):651-656.
48. Ma S., Ma C.C. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 2011, 22(3):167-175.
49. Maack C., Kartes T., Kilter H., Schafers H.J., Nickenig G., Bohm M., Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108(13):1567-1574.
50. Mehta J.L., Chen L.Y., Kone B.C., Mehta P., Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. Clin. Med. 1995, 125(3):370-377.
51. Miki H., Takenawa T. Regulation of actin dynamics by WASP family proteins. J. Biochem. 2003, 134(3):309-313.
52. Miki H., Suetsugu S., Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 1998, 17(23):6923-6941.
53. Murthy S., Ryan A., He C., Mallampalli R.K., Carter A.B. Rac1-mediated mitochondrial H202 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. J. Biol. Chem. 2010, 285(32):25062-25073.
54. Nakagawa M., Fukata M., Yamaga M., Itoh N., Kaibuchi K. Recruitment and activation of Rac1 by the formation of E-cadherin-mediated cell-cell adhesion sites. J. Cell Sci. 2001, 114(Pt 10):1829-1838.
55. Pignatelli P., Carnevale R., Cangemi R., Loffredo L., Sanguigni V., Stefanutti C., Basili S., Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2010, 30(2):360-367.
56. Pracyk J.B., Tanaka K., Hegland D.D., Kim K.S., Sethi R., Rovira I.I., et al. A requirement for the Rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J. Clin. Invest. 1998, 102(5):929-937.
57. Raihimi K., Emberson J., McGale P., Majoni W., Merhi A., Asselbergs F.W., Krane V., Macfarlane P.W. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomized controlled trials. BMJ 2011, 342:d1250.
58. Ray R., Murdoch C.E., Wang M., Santos C.X., Zhang M., Alom-Ruiz S., et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler. Thromb. Vasc. Biol. 2011, 31(6):1368-1376.
59. Reilly S.N., Jayaraam R., Nahar K., Antoniades C., Verheule S., Channon K.M., Alp N.J., Schotten U., Casadei B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011, 124(10):1107-1117.
60. Roe N.D., Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascul. Pharmacol. 2012, 57(5-6):168-172.
61. Rolli-Derkinderen M., Toumaniantz G., Pacaud P., Loirand G. RhoA phosphorylation induces Rac1 release from guanine dissociation inhibitor α and stimulation of vascular smooth muscle cell migration. Mol. Cell. Biol. 2010, 30(20):4786-4796.
62. Sanders L.C., Matsumura F., Bokoch G.M., de Lancrolle P. Inhibition of myosin light chain kinase by p21-activated kinase. Science 1999, 283(5410):2083-2085.
63. Sawada N., Liao J.K. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev. Neurother. 2009, 9(8):1171-1186.
64. Schramm A., Matusik P., Osmenda G., Guzik T.J. Targeting NADPH oxidases in vascular pharmacology. Vascul. Pharmacol. 2012, 56(5-6):216-231.
65. Schroder K., Zhang M., Benkhoff S., Mieth A., Pliquett R., Kosowski J., Sugawara T., Ayer R., Jadhav V., Chen W., Tsubokawa T., Zhang J.H. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ. Res. 2012, 110(9):1217-1225.
66. Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003, 108(4):426-431.
67. Sugawara T., Ayer R., Jadhav V., Chen W., Tsubokawa T., Zhang J.H. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J. Neurosci. Res. 2008, 86(16):3635-3643.
68. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275(13):3249-3277.
69. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 2001, 108(10):1429-1437.
70. Takenawa T., Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat. Rev. Mol. Cell Biol. 2007, 8(1):37-48.
71. Tsai C.T., Lai L.P., Kuo K.T., Hwang J.J., Hsieh C.S., Hsu K.L., Tseng C.D., Tseng Y.Z., Chiang F.T., Lin J.L. Angiotensin II activates signal tranducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodelling. Circulation 2008, 117(3):344-355.
72. von Lohneysen K., Noack D., Wood M.R., Friedman J.S., Knaus U.G. Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. Mol. Cell. Biol. 2010, 30(4):961-975.
73. Wattigney W.A., Mensah G.A., Croft J.B. Increased atrial fibrillation mortality: United States, 1980-1998. Am. J. Epidemiol. 2002, 155(9):819-826.
74. Wennerberg K., Der C.J. Rho-family GTPases: it's not only Rac and Rho (and I like it). J. Cell Sci. 2004, 117(Pt 8):1301-1312.
75. Wennerberg K., Rossman K.L., Der C.J. The Ras superfamily at a glance. J. Cell Sci. 2005, 118(Pt 5):843-846.
76. Werner E., Werb Z. Intergrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. J. Cell Biol. 2002, 158(2):357-368.
77. Whaley-Connell A., Habibi J., Nistala R., Cooper S.A., Karuparthi P.R., Hayden M.R., et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008, 51(2):474-480.
78. Wind S., Beuerlein K., Armitage M.E., Taye A., Kumar A.H., Janowitz D., et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 2010, 56(3):490-497.
79. Wingler K., Hermans J.J., Schiffers P., Moens A., Paul M., Schmidt H.H. Nox1,2,4,5: counting out oxidative stress. Br. J. Pharmacol. 2011, 164(3):866-883.
80. Woodruff T.M., Thundyil J., Tang S.C., Sobey C.G., Taylor S.M., Arumugam T.V. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol. Neurodegener. 2011, 6(1):11.
81. Xu Q., Guan Y.Q., Zhang D., Su G.H. The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials. Curr. Med. Res. Opin. 2011, 27(9):1771-1779.
82. Yang N., Higuchi O., Ohashi K., Nagata K., Wada A., Kangawa K., Nishida E., Mizuno K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998, 393(6687):809-812.
83. 2-elevated by oxidized LDL enhances human aortic smooth muscle cell proliferation. J. Biomed. Sci. 2007, 14(2):245-254.
84. Yu L., Quinn M.T., Cross A.R., Dinauer M.C. Gp91 (phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(14):7993-7998.
85. Yuzawa S., Miyano K., Honbou K., Inagaki F., Sumimoto H. The domain organization of p67 phox, a protein required for activation of the superoxide-producing NADPH oxidase in phagocytes. J. Innate Immun. 2009, 1(6):543-555.
86. Zhang M., Brewer A.C., Schroder K., Santos C.X., Grieve D.J., Wang M., et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(42):18121-18126.
87. Zhang J., Youn J.Y., Kim A.Y., Ramirez R.J., Gao L., Ngo D., Cheng P., Scovotti J., Mahajan A., Cai H. NOX-4 dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: relationship to hypertension. Front. Physiol. 2012, 3(140).